Cargando…

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease

Intestinal Behçet’s disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet’s disease is difficult to treat and often requires surgery because of the failure of...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jihye, Cheon, Jae Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254627/
https://www.ncbi.nlm.nih.gov/pubmed/29788675
http://dx.doi.org/10.5009/gnl17462
_version_ 1783373766061981696
author Park, Jihye
Cheon, Jae Hee
author_facet Park, Jihye
Cheon, Jae Hee
author_sort Park, Jihye
collection PubMed
description Intestinal Behçet’s disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet’s disease is difficult to treat and often requires surgery because of the failure of conventional medical treatment. Administration of anti-tumor necrosis factor–α, a potential therapeutic strategy, is currently under active clinical investigation, and evidence of its effectiveness for both intestinal Behçet’s disease and inflammatory bowel diseases has been accumulating. Here, we review updated data on current experiences and outcomes after the administration of anti-tumor necrosis factor–α for the treatment of intestinal Behçet’s disease. In addition to infliximab and adalimumab, which are the most commonly used agents, we describe agents such as golimumab, etanercept, and certolizumab pegol, which have recently been shown to be effective in refractory intestinal Behçet’s disease. This review also discusses safety issues associated with anti-tumor necrosis factor–α, including vulnerability to infections and malignancy.
format Online
Article
Text
id pubmed-6254627
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Editorial Office of Gut and Liver
record_format MEDLINE/PubMed
spelling pubmed-62546272018-11-26 Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease Park, Jihye Cheon, Jae Hee Gut Liver Review Intestinal Behçet’s disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet’s disease is difficult to treat and often requires surgery because of the failure of conventional medical treatment. Administration of anti-tumor necrosis factor–α, a potential therapeutic strategy, is currently under active clinical investigation, and evidence of its effectiveness for both intestinal Behçet’s disease and inflammatory bowel diseases has been accumulating. Here, we review updated data on current experiences and outcomes after the administration of anti-tumor necrosis factor–α for the treatment of intestinal Behçet’s disease. In addition to infliximab and adalimumab, which are the most commonly used agents, we describe agents such as golimumab, etanercept, and certolizumab pegol, which have recently been shown to be effective in refractory intestinal Behçet’s disease. This review also discusses safety issues associated with anti-tumor necrosis factor–α, including vulnerability to infections and malignancy. Editorial Office of Gut and Liver 2018-11 2018-05-24 /pmc/articles/PMC6254627/ /pubmed/29788675 http://dx.doi.org/10.5009/gnl17462 Text en Copyright © 2018 by The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Park, Jihye
Cheon, Jae Hee
Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
title Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
title_full Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
title_fullStr Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
title_full_unstemmed Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
title_short Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
title_sort anti-tumor necrosis factor therapy in intestinal behçet’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254627/
https://www.ncbi.nlm.nih.gov/pubmed/29788675
http://dx.doi.org/10.5009/gnl17462
work_keys_str_mv AT parkjihye antitumornecrosisfactortherapyinintestinalbehcetsdisease
AT cheonjaehee antitumornecrosisfactortherapyinintestinalbehcetsdisease